$0.9301
0.7%
Downside
Day's Volatility :4.82%
Upside
4.15%
19.35%
Downside
52 Weeks Volatility :77.54%
Upside
72.16%
Period | Mink Therapeutics, Inc. | |
---|---|---|
3 Months | 8.14% | |
6 Months | -21.84% | |
1 Year | -48.9% | |
3 Years | -92.25% |
Market Capitalization | 30.2M |
Book Value | - $0.52 |
Earnings Per Share (EPS) | -0.65 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -110.1% |
Return On Equity TTM | -1238.98% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -22.7M |
Diluted Eps TTM | -0.65 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.56 |
EPS Estimate Next Year | -0.6 |
EPS Estimate Current Quarter | -0.15 |
EPS Estimate Next Quarter | -0.15 |
What analysts predicted
Upside of 760.12%
Sell
Neutral
Buy
Mink Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Mink Therapeutics, Inc. | -29.54% | -21.84% | -48.9% | -92.25% | -92.25% |
Moderna, Inc. | 15.21% | 69.71% | -8.11% | -23.64% | 414.32% |
Regeneron Pharmaceuticals, Inc. | 3.36% | 17.89% | 28.96% | 93.09% | 194.82% |
Novo Nordisk A/s | -0.13% | 25.09% | 51.14% | 233.74% | 425.88% |
Vertex Pharmaceuticals Incorporated | 1.49% | 8.83% | 19.22% | 92.69% | 142.73% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Mink Therapeutics, Inc. | NA | NA | NA | -0.56 | -12.39 | -1.1 | NA | -0.52 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Mink Therapeutics, Inc. | Buy | $30.2M | -92.25% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 414.32% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 194.82% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 425.88% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 142.73% | 28.81 | 36.68% |
Vanguard Group Inc
Longbow Finance SA
Renaissance Technologies Corp
Geode Capital Management, LLC
BlackRock Inc
CapTrust Financial Advisors
Mink Therapeutics, Inc.’s price-to-earnings ratio stands at None
Read MoreOrganization | Mink Therapeutics, Inc. |
Employees | 31 |
CEO | Dr. Garo H. Armen Ph.D. |
Industry | Services |
Stitch Fix, Inc. (class A Shares)
$0.93
-1.13%
Gigacloud Technology Inc
$0.93
-1.13%
One Group Hospitality Inc/th
$0.93
-1.13%
Gh Research Plc
$0.93
-1.13%
Netstreit Corp
$0.93
-1.13%
Barrett Business Services Inc
$0.93
-1.13%
Sunlands Online Education Group
$0.93
-1.13%
Skillsoft Corp
$0.93
-1.13%
Telecom Argentina S.a.
$0.93
-1.13%